Phaseline

Companies › Atamyo Therapeutics

Atamyo Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Neurology; next expected readout Sep 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATA-100
AAV9 gene therapy delivering FKRP gene
FKRPPhase 1LGMDR9Sep 2029
ATA-200
SGCG gene replacement therapy
SGCGPhase 1LGMD2CJan 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05224505ATA-100Phase 1LGMDR9NeurologySep 2029
NCT05973630ATA-200Phase 1LGMD2CNeurologyJan 2031

Targets

SGCG (1) FKRP (1)

Companies with the same targets

AskBio ML Bio Solutions

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.